MMP9 and pulmonary arterial hypertension: In a study of 206 PAH patients, angiopoietin 1 (Ang-1), VEGF and matrix metallopeptidase 9 (MMP-9) levels have been associated with increased risk of death and hospitalization at the 16-week follow-up point after baseline [101].